393 related articles for article (PubMed ID: 24874015)
21. Alisertib, an Aurora kinase A inhibitor, induces apoptosis and autophagy but inhibits epithelial to mesenchymal transition in human epithelial ovarian cancer cells.
Ding YH; Zhou ZW; Ha CF; Zhang XY; Pan ST; He ZX; Edelman JL; Wang D; Yang YX; Zhang X; Duan W; Yang T; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():425-64. PubMed ID: 25624750
[TBL] [Abstract][Full Text] [Related]
22. Polo-Like Kinase 1 Pharmacological Inhibition as Monotherapy or in Combination: Comparative Effects of Polo-Like Kinase 1 Inhibition in Medulloblastoma Cells.
Pezuk JA; Brassesco MS; Ramos PMM; Scrideli CA; Tone LG
Anticancer Agents Med Chem; 2017; 17(9):1278-1291. PubMed ID: 28270075
[TBL] [Abstract][Full Text] [Related]
23. BI2536, a potent and selective inhibitor of polo-like kinase 1, in combination with cisplatin exerts synergistic effects on gastric cancer cells.
Lian G; Li L; Shi Y; Jing C; Liu J; Guo X; Zhang Q; Dai T; Ye F; Wang Y; Chen M
Int J Oncol; 2018 Mar; 52(3):804-814. PubMed ID: 29393385
[TBL] [Abstract][Full Text] [Related]
24. Modeling the mitotic regulatory network identifies highly efficient anti-cancer drug combinations.
Wu Y; Zhuo X; Dai Z; Guo X; Wang Y; Zhang C; Lai L
Mol Biosyst; 2015 Feb; 11(2):497-505. PubMed ID: 25418836
[TBL] [Abstract][Full Text] [Related]
25. Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia.
Chiarini F; Falà F; Tazzari PL; Ricci F; Astolfi A; Pession A; Pagliaro P; McCubrey JA; Martelli AM
Cancer Res; 2009 Apr; 69(8):3520-8. PubMed ID: 19351820
[TBL] [Abstract][Full Text] [Related]
26. Discovery of Inhibitors of Aurora/PLK Targets as Anticancer Agents.
Qi B; Zhong L; He J; Zhang H; Li F; Wang T; Zou J; Lin YX; Zhang C; Guo X; Li R; Shi J
J Med Chem; 2019 Sep; 62(17):7697-7707. PubMed ID: 31381325
[TBL] [Abstract][Full Text] [Related]
27. Aurora kinases as targets in drug-resistant neuroblastoma cells.
Michaelis M; Selt F; Rothweiler F; Löschmann N; Nüsse B; Dirks WG; Zehner R; Cinatl J
PLoS One; 2014; 9(9):e108758. PubMed ID: 25268132
[TBL] [Abstract][Full Text] [Related]
28. Pharmaceutically inhibiting polo-like kinase 1 exerts a broad anti-tumour activity in retinoblastoma cell lines.
Schwermer M; Dreesmann S; Eggert A; Althoff K; Steenpass L; Schramm A; Schulte JH; Temming P
Clin Exp Ophthalmol; 2017 Apr; 45(3):288-296. PubMed ID: 27647547
[TBL] [Abstract][Full Text] [Related]
29. Sensitivity of TP53-Mutated Cancer Cells to the Phytoestrogen Genistein Is Associated With Direct Inhibition of Plk1 Activity.
Shin SB; Woo SU; Chin YW; Jang YJ; Yim H
J Cell Physiol; 2017 Oct; 232(10):2818-2828. PubMed ID: 27861885
[TBL] [Abstract][Full Text] [Related]
30. Marsdenia tenacissimae extraction (MTE) inhibits the proliferation and induces the apoptosis of human acute T cell leukemia cells through inactivating PI3K/AKT/mTOR signaling pathway via PTEN enhancement.
Wang Y; Chen B; Wang Z; Zhang W; Hao K; Chen Y; Li K; Wang T; Xie Y; Huang Z; Tong X
Oncotarget; 2016 Dec; 7(50):82851-82863. PubMed ID: 27756877
[TBL] [Abstract][Full Text] [Related]
31. Targeted Polo-like Kinase Inhibition Combined With Aurora Kinase Inhibition in Pediatric Acute Leukemia Cells.
Jayanthan A; Hofmann B; Meier-Stephenson V; Perinpanayagam M; Dunn SE; Boklan J; Trippett TM; Truong TH; Narendran A
J Pediatr Hematol Oncol; 2019 Aug; 41(6):e359-e370. PubMed ID: 30702467
[TBL] [Abstract][Full Text] [Related]
32. Modulation of the Allosteric Communication between the Polo-Box Domain and the Catalytic Domain in Plk1 by Small Compounds.
Raab M; Sanhaji M; Pietsch L; Béquignon I; Herbrand AK; Süß E; Gande SL; Caspar B; Kudlinzki D; Saxena K; Sreeramulu S; Schwalbe H; Strebhardt K; Biondi RM
ACS Chem Biol; 2018 Aug; 13(8):1921-1931. PubMed ID: 29927572
[TBL] [Abstract][Full Text] [Related]
33. The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells.
Li JP; Yang YX; Liu QL; Pan ST; He ZX; Zhang X; Yang T; Chen XW; Wang D; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1627-52. PubMed ID: 25834401
[TBL] [Abstract][Full Text] [Related]
34. Molecular effects of the phosphatidylinositol-3-kinase inhibitor NVP-BKM120 on T and B-cell acute lymphoblastic leukaemia.
Pereira JK; Machado-Neto JA; Lopes MR; Morini BC; Traina F; Costa FF; Saad ST; Favaro P
Eur J Cancer; 2015 Sep; 51(14):2076-85. PubMed ID: 26238016
[TBL] [Abstract][Full Text] [Related]
35. Combined SRPK and AKT pharmacological inhibition is synergistic in T-cell acute lymphoblastic leukemia cells.
Siqueira RP; Caetano MMM; de Souza LÂ; Dos Passos PMS; Simaroli NB; Barros MVA; de Souza APM; de Oliveira LL; Silva-Júnior A; Fietto JLR; Teixeira RR; Teixeira FR; Bressan GC
Toxicol In Vitro; 2020 Jun; 65():104777. PubMed ID: 31962201
[TBL] [Abstract][Full Text] [Related]
36. Designed inhibitor for nuclear localization signal of polo-like kinase 1 induces mitotic arrest.
Chen F; Zhuo X; Qin T; Guo X; Zhang C; Lai L
Chem Biol Drug Des; 2017 May; 89(5):732-740. PubMed ID: 27882722
[TBL] [Abstract][Full Text] [Related]
37. A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma.
Lin YW; Beharry ZM; Hill EG; Song JH; Wang W; Xia Z; Zhang Z; Aplan PD; Aster JC; Smith CD; Kraft AS
Blood; 2010 Jan; 115(4):824-33. PubMed ID: 19965690
[TBL] [Abstract][Full Text] [Related]
38. Survival of primary, but not of cancer cells after combined Plk1-HDAC inhibition.
Lange L; Hemmerich P; Spänkuch B
Oncotarget; 2015 Sep; 6(28):25801-14. PubMed ID: 26317649
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis, and biological evaluation of 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridine derivatives as novel dual-PLK1/BRD4 inhibitors.
Wang NY; Xu Y; Xiao KJ; Zuo WQ; Zhu YX; Hu R; Wang WL; Shi YJ; Yu LT; Liu ZH
Eur J Med Chem; 2020 Apr; 191():112152. PubMed ID: 32088495
[TBL] [Abstract][Full Text] [Related]
40. Targeting of polo-like kinases and their cross talk with Aurora kinases--possible therapeutic strategies in human acute myeloid leukemia?
Tsykunova G; Reikvam H; Ahmed AB; Nepstad I; Gjertsen BT; Bruserud Ø
Expert Opin Investig Drugs; 2012 May; 21(5):587-603. PubMed ID: 22424119
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
